cdmo.directory
← Back to posts

CDMO Daily News — November 20, 2026

By BioBM ·

At a glance

Related topics: Manufacturing capacity

Gene2Cure Collaborates with Viralgen to Manufacture Gene Therapies for Rare Diseases

Operational Impact

This collaboration enhances Viralgen's role in gene therapy manufacturing, potentially increasing capacity for rare disease treatments.

Source: PharmaSource RSS


OXB Partners with Aura Biosciences for Phase 3 Manufacturing of Ocular Cancer Therapy

Operational Impact

This partnership allows OXB to expand its manufacturing capabilities into virus-like drug conjugates while supporting Aura's late-stage clinical development.

Source: PharmaSource RSS

References

  1. PharmaSource RSS — Gene2Cure Collaborates with Viralgen to Manufacture Gene Therapies for Rare Diseases
  2. PharmaSource RSS — OXB Partners with Aura Biosciences for Phase 3 Manufacturing of Ocular Cancer Therapy

Deep dive by email

Get the next CDMO deep dive by email. One message when it publishes. No daily digest.

Markdown mirror: /posts/daily-news-2026-11-20-cdmo.md